This is the fourth in a series of articles designed to provide SXSW and LSI USA ’26 attendees and other MedTech professionals with practical considerations for efficiently executing mission-critical life science deals.
Many MedTech companies begin with one important relationship.
A health system agrees to test the product.
A strategic customer agrees to move first.
A commercial partner helps validate the market.
That is often how the first traction happens.
This is the second in a series of articles designed to provide SXSW and LSI USA ’26 attendees and other MedTech professionals with practical considerations for efficiently executing mission-critical life science deals.
Collaborations often start with a simple premise: build something together, share the risk, and create value.
The complexity shows up later when investors or buyers ask who actually owns the platform.
In co-development structures involving devices and software, ownership and control are rarely binary. They are defined by layered licensing arrangements, regulatory allocations, manufacturing dependencies, and IP assignments that were often negotiated quickly to get a deal done.
Throughout this series, we’ve explored the key elements of successful life sciences transactions—from structuring collaborations and securing funding to protecting intellectual property and navigating regulatory complexities.
Yet, even when companies understand these fundamentals, transactions don’t always go as planned. In our work with biotech, medtech, digital health, and research-driven companies, we’ve seen common missteps that can slow deals down, create compliance risks, or weaken long-term business outcomes.
With the SXSW Health and MedTech conference in full swing, it’s a good time to reflect on some fundamental Intellectual Property (IP) strategies that can help safeguard your Life Sciences and MedTech business and maximize its value now and into the future.
IP is often one of the most valuable assets a company can own. Whether you’re preparing to sell a business, enter into a joint venture, or acquire another company, understanding the scope of your IP portfolio is essential. For in-house counsel, founders, corporate executives, and other legal professionals, navigating the complexities of IP ownership and licensing can make or break a deal.
AI, Medical Devices, Digital Health, and the Future of Healthcare Transactions
Innovation in life sciences isn’t just about scientific breakthroughs—it’s about making the right business decisions.